

## Invitation to the presentation of BICO's Interim report Q1 2026

**BICO's Interim report 2026 will be published on Wednesday April 29, 2026, at 07:00am CEST. Following the release of the interim report, a telephone conference with the opportunity to ask questions will be held in English at 10:00 am CEST on the same day, with President & CEO Maria Forss and CFO Ewa Linsäter presenting the interim report.**

Information about the presentation and webcast  
The presentation will be available on BICO's website from 09:00am CEST.  
<https://bico.com/investors/>

If you wish to participate via webcast, please use the link below:  
<https://bico.events.inderes.com/q1-report-2026>

If you wish to participate via teleconference, please register via the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via teleconference.  
<https://events.inderes.com/bico/q1-report-2026/dial-in>

**For further information, please contact:**  
Ewa Linsäter, Chief Financial Officer, BICO Group AB  
Phone: +46 766 33 32 33  
E-mail: [ewa.linsater@bico.com](mailto:ewa.linsater@bico.com)

*The information was submitted for publication, through the agency of the contact person set out above on April 15, 2026, at 07.00am CEST.*

### About BICO

**BICO** is a lab automation partner and provider of selected workflows to pharma and biotech. With 53,600+ instruments installed in over 65 countries, BICO products, software, and solutions are found in more than 3,500 laboratories, including the world's top 20 pharmaceutical companies, and have been cited in over 12,900 publications. BICO strives towards the vision to enable and automate the life science lab of the future. BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. [www.bico.com](http://www.bico.com)

### Attachments

[Invitation to the presentation of BICO's Interim report Q1 2026](#)